Last reviewed · How we verify

HA Chemotherapy

Duke University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

HA Chemotherapy is a Small molecule drug developed by Duke University. It is currently FDA-approved.

HA Chemotherapy is a treatment modality that involves the use of small molecule hyaluronic acid (HA) to target various conditions, including hypogonadism, hypergonadism, precocious puberty, late puberty, and amenorrhea. The exact mechanism of HA Chemotherapy is not specified, but it is known to be administered through different interventions, such as hyaluronate gel for injection, polycaprolactone microsphere filler, and hyaluronic acid.

At a glance

Generic nameHA Chemotherapy
SponsorDuke University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HA Chemotherapy

What is HA Chemotherapy?

HA Chemotherapy is a Small molecule drug developed by Duke University.

Who makes HA Chemotherapy?

HA Chemotherapy is developed and marketed by Duke University (see full Duke University pipeline at /company/duke-university).

What development phase is HA Chemotherapy in?

HA Chemotherapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing